A team of international researchers led by Prof Martin Hegner, Investigator in CRANN and Trinity’s School of Physics developed an automated diagnostic platform that indicates bleeding – and thrombotic risks in one drop of blood within seconds (Nanoscale, “Towards personalised rapid label free miRNA detection for cancer and liver injury diagnostics in cell lysates and blood based samples”).

They exploit micro-resonators for real-time measurements of the evolving blood plasma clot strength. Along with the clinically measured clotting time, other parameters, from specific factor deficiency to global coagulation parameters to assess fibrinolysis, can be extracted.

These technical developments now open up the possibility to introduce a miniaturized global haemostasis assay with capability to fine-tune anti-coagulation therapies.

In collaboration with the multinational Hoffman-la-Roche they report a novel strategy for quick, reliable and quantitative diagnostics of expression patterns of non-coding short RNA in blood plasma or cell cultures. They directly detect label-free specific miRNA biomarkers relevant to cancer and adverse drug effects in blood-based samples (right image).

 

Read more at nanowerk.com

Image Credit:  CRANN

News This Week

Visualizing the Healthtech Revolution

Imagine being a patient in the early 19th century, when all ailments were considered “humors” to be ejected from the body. To restore balance, various techniques such as diets, natural herbs, or bloodletting with [...]